Solasia Pharma K.K. (TYO:4597)

Japan · Delayed Price · Currency is JPY

27.00

+1.00 (3.85%)

Oct 23, 2026, 3:30 PM JST

Market Cap	7.37B -17.6%
Revenue (ttm)	388.00M +32.4%
Net Income	-900.00M
EPS	-3.42
Shares Out	273.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,928,900
Open	26.00
Previous Close	26.00
Day's Range	25.00 - 27.00
52-Week Range	21.00 - 42.00
Beta	1.18
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical t... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2006

Employees 22

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4597

Full Company Profile

Financial Performance

In 2025, Solasia Pharma K.K.'s revenue was 429.00 million, an increase of 35.76% compared to the previous year's 316.00 million. Losses were -876.00 million, -54.87% less than in 2024.

Financial Statements